Nasal spray to treat anxiety moves forward with global phase 3 trial

VistaGen Therapeutics and AffaMed Therapeutics announced a global phase 3 trial to assess the efficacy, safety and tolerability of a nasal spray that treats adults with social anxiety disorders.
Dubbed the PALISADE Global trial, the companies have submitted necessary data to the FDA under its existing PH94B investigational new drug application for the nasal spray. The trial is expected to begin in the United States and China in the second half of 2022.
PH94B is odorless, fast-acting neuroactive spray with a potential mechanism of action for the acute treatment of anxiety in adults.
“VistaGen

VistaGen Therapeutics and AffaMed Therapeutics announced a global phase 3 trial to assess the efficacy, safety and tolerability of a nasal spray that treats adults with social anxiety disorders.
Dubbed the PALISADE Global trial, the companies have submitted necessary data to the FDA under its existing PH94B investigational new drug application for the nasal spray. The trial is expected to begin in the United States and China in the second half of 2022.
PH94B is odorless, fast-acting neuroactive spray with a potential mechanism of action for the acute treatment of anxiety in adults.
“VistaGen